• Developing Safe, Effective Medicines for All Ages

    Clinical trials allow for the development of medicines that are safe and effective for people of all ages—including kids. Yet kids are not just little adults, and pediatric clinical trials must be des…

  • What’s Next in Alzheimer’s Disease

    This guest post is authored by Dan Skovronsky, Senior Vice President of Product and Clinical Development at Lilly. For nearly 30 years, Lilly has worked to fight Alzheimer’s disease, and despite rece…

  • Fighting childhood cancer

    The need for Public-Private Partnership By Dr Louis Stancato, Senior Research Advisor, Oncology TME & Translational Research, Eli Lilly & Company  Back in June, LillyPadEU reported on the nee…

  • Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis

    INDIANAPOLIS, Sept. 14, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced new safety and efficacy data from a Phase 2 study of baricitinib in…

  • Using Real-World Evidence to Deliver Innovation in Cancer Care

    Today’s guest blog comes from Lilly scientist Symantha (Sam) Melemed, Ph.D., a product team leader in the Lilly Oncology group. As a researcher, it’s the hope that we’ll find “the one” – the treatment…